The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

  • STATUS
    Recruiting
  • days left to enroll
    21
  • participants needed
    100
  • sponsor
    Hangzhou Highlightll Pharmaceutical Co., Ltd
Send
Updated on 25 April 2022
See if I qualify
methotrexate
tofacitinib
hydroxychloroquine
DMARD
sulfasalazine
rheumatism
leflunomide
chloroquine
rheumatoid factor
antirheumatics

Summary

This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had an inadequate response or intolerance to methotrexate.

Details
Condition Rheumatoid Arthritis
Treatment tofacitinib, TLL-018
Clinical Study IdentifierNCT05133297
SponsorHangzhou Highlightll Pharmaceutical Co., Ltd
Last Modified on25 April 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Diagnosed with RA based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 ACR/European League against Rheumatism (EULAR) criteria and have an inadequate response or intolerance to methotrexate
Subjects must have been receiving oral or parenteral methotrexate therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to Baseline Visit
Have active RA as defined by the following minimum disease activity criteria
≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline Visits
≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits
high-sensitivity C-reactive protein (hsCRP) > upper limit of normal (ULN) OR positive for both rheumatoid factor and anti-cyclic citrullinated peptide (CCP) at Screening
For subjects with inadequate response to methotrexate, subjects must have discontinued
all oral disease-modifying anti-rheumatic drugs (DMARDs) prior to Baseline
Visit as specified below or for at least five times the mean terminal
elimination half-life of a drug, whichever is longer
≥4 weeks prior to Baseline Visit for minocycline, penicillamine, sulfasalazine, hydroxychloroquine, chloroquine, azathioprine, gold formulations, cyclophosphamide
≥12 weeks prior to Baseline Visit for leflunomide if no elimination procedure was followed, or adhere to a washout procedure (i.e., 11 days washout with colestyramine, or 30 days washout with activated charcoal)
The organ function level must meet the following requirements
Bone marrow: Blood routine results showed hemoglobin ≥90g/L, platelet ≥100×109/L
neutrophil absolute count ≥1.5×109/L; Liver: serum bilirubin ≤1.5 times the upper limit of
normal value, aspartate aminotransferase (AST) ≤1.5 times the upper limit of normal value
alanine aminotransferase (ALT) ≤1.5 times the upper limit of normal value; Serum creatinine
<1.5 times the upper limit of normal value; Urine protein ≤1+, if urine protein >1+, urine
protein should be collected for 24 hours, the total amount should be ≤1 g. Female subjects
of childbearing potential must test negative for pregnancy

Exclusion Criteria

History of Felty syndrome (Rheumatoid arthritis - Splenomegaly syndrome)
A history of herpes zoster or disseminated herpes simplex
Treatment with any JAK inhibitor (tofacitinib, baricitinib, ruxolitinib) within 2
weeks prior to study start
Subjects have severe, progressive or uncontrollable symptoms of kidney, liver, blood
gastrointestinal, lung, cardiovascular, neurological or brain disease
Current treatment or treatment within 4 weeks or 5 half-lives (whichever is longer)
prior to the first dose of study medication with another investigational medication or
current enrollment in another investigational drug protocol
If the laboratory T-Spot test (or other TB diagnostic test) is positive, the
investigator will determine the activity based on the history and clinical
manifestations, and the patients diagnosed as active TB should be excluded
Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface
antigen (HBsAg), or hepatitis C antibody
Pregnant or breastfeeding female
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

methotrexate
tofacitinib
hydroxychloroquine
DMARD
sulfasalazine
rheumatism
leflunomide
chloroquine
rheumatoid factor
antirheumatics

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note